| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.895 | 0.001 | 0.895 | Growth hormone secretagogue receptor antagonist | 0.768 0.002 DBMET02227 0.042 0.021 DBMET02228 0.101 0.007 DBMET02229 | ||
| 0.75 | 0.002 | 0.854 | Tyrosine 3 hydroxylase inhibitor | 0.854 0.001 DBMET02227 0.59 0.003 DBMET02228 0.517 0.004 DBMET02229 | DBMET02227 | |
| 0.723 | 0.005 | 0.724 | 5 Hydroxytryptamine release stimulant | 0.724 0.005 DBMET02227 0.48 0.031 DBMET02228 0.53 0.023 DBMET02229 | DBMET02227 | |
| 0.676 | 0.003 | 0.676 | Growth hormone agonist | 0.606 0.004 DBMET02227 0.384 0.018 DBMET02228 0.303 0.032 DBMET02229 | ||
| 0.56 | 0.002 | 0.56 | GHS receptor antagonist | 0.356 0.002 DBMET02227 0.031 0.025 DBMET02228 0.04 0.012 DBMET02229 | ||
| 0.55 | 0.021 | 0.55 | Immunosuppressant | 0.525 0.027 DBMET02227 0.409 0.059 DBMET02228 | ||
| 0.533 | 0.028 | 0.608 | Cholesterol antagonist | 0.608 0.018 DBMET02227 0.309 0.085 DBMET02228 0.394 0.051 DBMET02229 | DBMET02227 | |
| 0.487 | 0.005 | 0.487 | 5 Hydroxytryptamine uptake stimulant | 0.477 0.005 DBMET02227 0.331 0.032 DBMET02228 0.358 0.023 DBMET02229 | ||
| 0.454 | 0.04 | 0.482 | GABA C receptor rho-3 antagonist | 0.482 0.031 DBMET02227 0.328 0.098 DBMET02228 0.373 0.074 DBMET02229 | DBMET02227 | |
| 0.447 | 0.053 | 0.472 | 5 Hydroxytryptamine release inhibitor | 0.472 0.042 DBMET02227 0.328 0.135 DBMET02228 0.349 0.116 DBMET02229 | DBMET02227 | |
| 0.44 | 0.052 | 0.44 | Antiobesity | 0.32 0.103 DBMET02227 | ||
| 0.417 | 0.03 | 0.44 | Vasodilator, coronary | 0.426 0.028 DBMET02227 0.274 0.111 DBMET02228 0.44 0.025 DBMET02229 | DBMET02229 | |
| 0.391 | 0.004 | 0.391 | ABCA1 expression enhancer | 0.3 0.005 DBMET02227 | ||
| 0.397 | 0.023 | 0.468 | Psychostimulant | 0.378 0.026 DBMET02227 0.468 0.014 DBMET02228 0.24 0.062 DBMET02229 | DBMET02228 | |
| 0.381 | 0.008 | 0.381 | Peptidyltransferase inhibitor | 0.374 0.009 DBMET02227 0.205 0.092 DBMET02229 | ||
| 0.368 | 0.002 | 0.368 | GHS receptor agonist | 0.255 0.003 DBMET02227 | ||
| 0.432 | 0.074 | 0.432 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.309 0.201 DBMET02227 0.325 0.18 DBMET02228 0.362 0.138 DBMET02229 | ||
| 0.422 | 0.067 | 0.484 | Calcium channel L-type activator | 0.484 0.034 DBMET02227 0.271 0.184 DBMET02228 0.428 0.064 DBMET02229 | DBMET02227 | |
| 0.353 | 0.002 | 0.353 | Calcium-sensing receptor antagonist | 0.225 0.002 DBMET02227 0.226 0.002 DBMET02228 0.343 0.002 DBMET02229 | ||
| 0.378 | 0.031 | 0.454 | Superoxide dismutase inhibitor | 0.454 0.018 DBMET02227 0.198 0.12 DBMET02228 0.304 0.049 DBMET02229 | DBMET02227 | |
| 0.344 | 0.002 | 0.344 | Growth hormone releasing factor agonist | 0.203 0.003 DBMET02227 0.048 0.014 DBMET02229 | ||
| 0.337 | 0.005 | 0.337 | Ferrochelatase inhibitor | 0.232 0.016 DBMET02227 0.197 0.023 DBMET02228 0.212 0.02 DBMET02229 | ||
| 0.351 | 0.028 | 0.533 | Peroxidase inhibitor | 0.529 0.007 DBMET02227 0.533 0.007 DBMET02228 0.141 0.083 DBMET02229 | DBMET02228 | |
| 0.317 | 0.005 | 0.438 | Histidine decarboxylase inhibitor | 0.438 0.003 DBMET02227 0.083 0.041 DBMET02228 0.157 0.018 DBMET02229 | DBMET02227 | |
| 0.311 | 0.009 | 0.311 | GABA C receptor agonist | 0.299 0.009 DBMET02227 0.16 0.03 DBMET02228 0.156 0.032 DBMET02229 | ||
| 0.35 | 0.05 | 0.363 | Calcium channel activator | 0.334 0.061 DBMET02227 0.298 0.094 DBMET02228 0.363 0.042 DBMET02229 | DBMET02229 | |
| 0.332 | 0.034 | 0.332 | Interleukin agonist | 0.323 0.038 DBMET02227 0.236 0.089 DBMET02228 0.281 0.058 DBMET02229 | ||
| 0.351 | 0.055 | 0.586 | Aldehyde oxidase inhibitor | 0.586 0.021 DBMET02227 0.172 0.121 DBMET02228 0.194 0.108 DBMET02229 | DBMET02227 | |
| 0.322 | 0.027 | 0.322 | Ca(v)3.3 blocker | 0.229 0.135 DBMET02227 0.227 0.139 DBMET02228 0.263 0.082 DBMET02229 | ||
| 0.297 | 0.003 | 0.312 | Bombesin 1 receptor antagonist | 0.098 0.004 DBMET02227 0.103 0.004 DBMET02228 0.312 0.002 DBMET02229 | DBMET02229 | |
| 0.325 | 0.034 | 0.325 | Anticonvulsant | 0.183 0.097 DBMET02227 | ||
| 0.36 | 0.07 | 0.394 | Vasodilator, peripheral | 0.369 0.066 DBMET02227 0.295 0.099 DBMET02228 0.394 0.057 DBMET02229 | DBMET02229 | |
| 0.286 | 0.002 | 0.286 | Growth hormone release promoting | 0.147 0.003 DBMET02227 0.03 0.01 DBMET02229 | ||
| 0.288 | 0.004 | 0.424 | Phenylalanine 4-hydroxylase inhibitor | 0.424 0.003 DBMET02227 0.358 0.003 DBMET02228 0.104 0.024 DBMET02229 | DBMET02227 | |
| 0.311 | 0.031 | 0.339 | Anesthetic general | 0.339 0.026 DBMET02227 0.179 0.087 DBMET02228 0.25 0.05 DBMET02229 | DBMET02227 | |
| 0.294 | 0.017 | 0.294 | Alpha-N-acetylglucosaminidase inhibitor | 0.26 0.021 DBMET02227 0.251 0.023 DBMET02228 0.257 0.022 DBMET02229 | ||
| 0.366 | 0.092 | 0.431 | Histamine release inhibitor | 0.431 0.059 DBMET02227 0.203 0.198 DBMET02228 0.299 0.124 DBMET02229 | DBMET02227 | |
| 0.275 | 0.003 | 0.368 | DOPA decarboxylase inhibitor | 0.368 0.002 DBMET02227 0.176 0.011 DBMET02228 0.235 0.004 DBMET02229 | DBMET02227 | |
| 0.277 | 0.011 | 0.277 | Bronchodilator | 0.274 0.011 DBMET02227 0.267 0.011 DBMET02228 0.234 0.014 DBMET02229 | ||
| 0.298 | 0.034 | 0.317 | Gastrin inhibitor | 0.25 0.08 DBMET02227 0.294 0.037 DBMET02228 0.317 0.023 DBMET02229 | DBMET02229 | |
| 0.298 | 0.04 | 0.298 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.222 0.076 DBMET02227 | ||
| 0.309 | 0.067 | 0.339 | Spasmolytic | 0.339 0.056 DBMET02227 0.161 0.153 DBMET02228 0.272 0.082 DBMET02229 | DBMET02227 | |
| 0.264 | 0.024 | 0.289 | Nitric-oxide synthase stimulant | 0.289 0.014 DBMET02227 0.208 0.076 DBMET02228 0.266 0.023 DBMET02229 | DBMET02227 | |
| 0.245 | 0.004 | 0.37 | Glutamate decarboxylase inhibitor | 0.37 0.003 DBMET02227 0.284 0.004 DBMET02228 0.145 0.014 DBMET02229 | DBMET02227 | |
| 0.238 | 0.005 | 0.238 | Sphingosine 1-phosphate receptor 4 antagonist | 0.21 0.007 DBMET02227 0.124 0.064 DBMET02228 0.216 0.006 DBMET02229 | ||
| 0.294 | 0.062 | 0.368 | Insulysin inhibitor | 0.309 0.053 DBMET02227 0.368 0.029 DBMET02228 0.206 0.148 DBMET02229 | DBMET02228 | |
| 0.247 | 0.017 | 0.247 | 5 Hydroxytryptamine 3E antagonist | 0.198 0.066 DBMET02227 0.188 0.085 DBMET02228 0.208 0.051 DBMET02229 | ||
| 0.232 | 0.005 | 0.232 | Sphingosine 1-phosphate receptor 5 antagonist | 0.229 0.005 DBMET02227 0.158 0.049 DBMET02228 0.184 0.02 DBMET02229 | ||
| 0.23 | 0.004 | 0.23 | Cholecystokinin A antagonist | 0.1 0.009 DBMET02227 0.091 0.01 DBMET02228 0.131 0.005 DBMET02229 | ||
| 0.229 | 0.007 | 0.375 | Creatine kinase inhibitor | 0.375 0.003 DBMET02227 0.122 0.039 DBMET02228 0.168 0.018 DBMET02229 | DBMET02227 | |
| 0.238 | 0.018 | 0.99 | Antiadrenergic | 0.183 0.028 DBMET02227 0.99 0.002 DBMET02229 | DBMET02229 | |
| 0.234 | 0.018 | 0.989 | Adrenaline antagonist | 0.18 0.028 DBMET02227 0.989 0.002 DBMET02229 | DBMET02229 | |
| 0.252 | 0.037 | 0.306 | Neurotrophic factor enhancer | 0.306 0.016 DBMET02227 0.184 0.093 DBMET02228 0.202 0.074 DBMET02229 | DBMET02227 | |
| 0.219 | 0.004 | 0.219 | Cholecystokinin antagonist | 0.083 0.011 DBMET02227 0.082 0.011 DBMET02228 0.121 0.006 DBMET02229 | ||
| 0.231 | 0.024 | 0.269 | Neurotensin receptor agonist | 0.269 0.018 DBMET02227 0.147 0.108 DBMET02228 0.213 0.029 DBMET02229 | DBMET02227 | |
| 0.227 | 0.022 | 0.315 | Aldehyde dehydrogenase inhibitor | 0.315 0.01 DBMET02227 0.113 0.079 DBMET02228 0.141 0.053 DBMET02229 | DBMET02227 | |
| 0.202 | 0.004 | 0.202 | Growth hormone secretagogue receptor agonist | 0.116 0.005 DBMET02227 | ||
| 0.228 | 0.031 | 0.243 | Succinate dehydrogenase inhibitor | 0.243 0.025 DBMET02227 0.179 0.069 DBMET02228 0.218 0.036 DBMET02229 | DBMET02227 | |
| 0.226 | 0.031 | 0.31 | Phospholipase C inhibitor | 0.31 0.017 DBMET02227 0.154 0.098 DBMET02228 0.151 0.104 DBMET02229 | DBMET02227 | |
| 0.344 | 0.15 | 0.445 | Caspase 9 stimulant | 0.415 0.102 DBMET02227 0.445 0.085 DBMET02228 0.385 0.12 DBMET02229 | DBMET02228 | |
| 0.219 | 0.028 | 0.219 | Nav1.2 sodium channel blocker | 0.171 0.046 DBMET02227 0.113 0.092 DBMET02228 0.124 0.079 DBMET02229 | ||
| 0.193 | 0.004 | 0.193 | Cholecystokinin B antagonist | 0.061 0.008 DBMET02227 0.062 0.008 DBMET02228 0.1 0.005 DBMET02229 | ||
| 0.198 | 0.013 | 0.255 | GABA C receptor antagonist | 0.193 0.014 DBMET02227 0.255 0.006 DBMET02228 0.115 0.058 DBMET02229 | DBMET02228 | |
| 0.201 | 0.021 | 0.258 | Aminopeptidase B inhibitor | 0.201 0.021 DBMET02227 0.258 0.012 DBMET02228 0.177 0.028 DBMET02229 | DBMET02228 | |
| 0.217 | 0.038 | 0.217 | Diuretic | 0.188 0.049 DBMET02227 | ||
| 0.185 | 0.008 | 0.265 | Adrenaline agonist | 0.265 0.004 DBMET02227 0.192 0.008 DBMET02229 | DBMET02227 | |
| 0.19 | 0.013 | 0.247 | Porphobilinogen synthase inhibitor | 0.247 0.008 DBMET02227 0.086 0.043 DBMET02228 0.158 0.019 DBMET02229 | DBMET02227 | |
| 0.192 | 0.017 | 0.262 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.163 0.023 DBMET02227 0.108 0.047 DBMET02228 0.262 0.009 DBMET02229 | DBMET02229 | |
| 0.281 | 0.106 | 0.397 | Transcription factor NF kappa B inhibitor | 0.397 0.064 DBMET02227 0.24 0.135 DBMET02229 | DBMET02227 | |
| 0.191 | 0.018 | 0.215 | Adenylate cyclase stimulant | 0.215 0.008 DBMET02227 0.197 0.015 DBMET02228 0.158 0.05 DBMET02229 | DBMET02227 | |
| 0.184 | 0.015 | 0.197 | HIV-1 integrase (Overall Integration) inhibitor | 0.197 0.012 DBMET02227 0.087 0.068 DBMET02228 0.132 0.033 DBMET02229 | DBMET02227 | |
| 0.174 | 0.005 | 0.174 | Sphingosine 1-phosphate receptor 4 agonist | 0.165 0.006 DBMET02227 0.06 0.055 DBMET02228 0.129 0.013 DBMET02229 | ||
| 0.182 | 0.014 | 0.182 | Sphingosine 1-phosphate receptor 2 antagonist | 0.182 0.014 DBMET02227 0.128 0.079 DBMET02228 0.136 0.063 DBMET02229 | ||
| 0.239 | 0.072 | 0.239 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.205 | 0.04 | 0.205 | Acetylcholine M1 receptor antagonist | 0.201 0.042 DBMET02227 | ||
| 0.176 | 0.013 | 0.176 | GABA C receptor rho-1 antagonist | 0.159 0.018 DBMET02227 0.104 0.057 DBMET02228 0.107 0.054 DBMET02229 | ||
| 0.185 | 0.026 | 0.185 | Nav1.6 sodium channel blocker | 0.156 0.048 DBMET02227 0.136 0.072 DBMET02229 | ||
| 0.185 | 0.027 | 0.185 | Cathepsin H inhibitor | 0.152 0.045 DBMET02227 0.116 0.081 DBMET02228 0.173 0.032 DBMET02229 | ||
| 0.189 | 0.035 | 0.189 | GABA C receptor rho-2 antagonist | 0.181 0.041 DBMET02227 0.144 0.082 DBMET02228 0.157 0.064 DBMET02229 | ||
| 0.17 | 0.016 | 0.17 | Nitric-oxide synthase inhibitor | 0.123 0.036 DBMET02227 0.1 0.06 DBMET02229 | ||
| 0.187 | 0.036 | 0.187 | Anesthetic local | 0.154 0.047 DBMET02227 0.153 0.047 DBMET02229 | ||
| 0.232 | 0.081 | 0.257 | DNA synthesis inhibitor | 0.257 0.062 DBMET02227 0.244 0.071 DBMET02229 | DBMET02227 | |
| 0.155 | 0.004 | 0.155 | Glutamate (mGluR6) antagonist | 0.131 0.005 DBMET02227 0.087 0.018 DBMET02228 0.088 0.017 DBMET02229 | ||
| 0.165 | 0.015 | 0.181 | Phosphofructokinase-1 inhibitor | 0.181 0.013 DBMET02227 0.118 0.026 DBMET02228 0.118 0.026 DBMET02229 | DBMET02227 | |
| 0.222 | 0.072 | 0.237 | RNA-directed DNA polymerase inhibitor | 0.237 0.058 DBMET02227 0.194 0.109 DBMET02229 | DBMET02227 | |
| 0.153 | 0.004 | 0.153 | Sphingosine 1-phosphate receptor 3 agonist | 0.12 0.005 DBMET02227 | ||
| 0.165 | 0.018 | 0.165 | Ca2+-transporting ATPase inhibitor | 0.164 0.018 DBMET02227 0.155 0.032 DBMET02228 0.161 0.022 DBMET02229 | ||
| 0.157 | 0.009 | 0.378 | Alcohol oxidase inhibitor | 0.378 0.004 DBMET02227 0.059 0.036 DBMET02228 0.103 0.017 DBMET02229 | DBMET02227 | |
| 0.163 | 0.02 | 0.163 | Sphingosine 1-phosphate receptor 2 agonist | 0.141 0.031 DBMET02227 | ||
| 0.189 | 0.048 | 0.194 | ATPase inhibitor | 0.194 0.043 DBMET02227 0.181 0.056 DBMET02228 0.176 0.062 DBMET02229 | DBMET02227 | |
| 0.187 | 0.046 | 0.199 | Arachidonic acid antagonist | 0.199 0.034 DBMET02227 0.167 0.069 DBMET02228 0.182 0.051 DBMET02229 | DBMET02227 | |
| 0.152 | 0.011 | 0.152 | Glutamate (mGluR7) agonist | 0.11 0.043 DBMET02227 0.094 0.072 DBMET02229 | ||
| 0.146 | 0.006 | 0.208 | Beta 3 adrenoreceptor antagonist | 0.208 0.004 DBMET02227 0.082 0.022 DBMET02228 0.149 0.006 DBMET02229 | DBMET02227 | |
| 0.159 | 0.02 | 0.214 | Calcium antagonist | 0.084 0.06 DBMET02227 0.091 0.055 DBMET02228 0.214 0.012 DBMET02229 | DBMET02229 | |
| 0.161 | 0.023 | 0.161 | Adenylate kinase inhibitor | 0.145 0.029 DBMET02227 0.139 0.031 DBMET02228 0.142 0.03 DBMET02229 | ||
| 0.181 | 0.042 | 0.183 | Hemostatic | 0.183 0.041 DBMET02227 0.122 0.11 DBMET02228 | DBMET02227 | |
| 0.152 | 0.016 | 0.152 | Inducible nitric-oxide synthase inhibitor | 0.115 0.027 DBMET02227 0.083 0.057 DBMET02229 | ||
| 0.146 | 0.012 | 0.146 | Carbamoyl phosphate synthetase inhibitor | 0.138 0.013 DBMET02227 0.068 0.036 DBMET02228 0.069 0.035 DBMET02229 | ||
| 0.146 | 0.013 | 0.146 | Aminopeptidase I inhibitor | 0.139 0.014 DBMET02227 0.096 0.03 DBMET02228 0.099 0.028 DBMET02229 | ||
| 0.145 | 0.013 | 0.155 | Ornithine decarboxylase inhibitor | 0.155 0.01 DBMET02227 0.086 0.06 DBMET02228 0.09 0.056 DBMET02229 | DBMET02227 | |
| 0.229 | 0.098 | 0.229 | 5 Hydroxytryptamine 1E antagonist | 0.218 0.11 DBMET02227 0.217 0.112 DBMET02229 | ||
| 0.173 | 0.044 | 0.203 | CF transmembrane conductance regulator agonist | 0.203 0.02 DBMET02227 0.155 0.068 DBMET02229 | DBMET02227 | |
| 0.149 | 0.021 | 0.244 | Alcohol dehydrogenase inhibitor | 0.244 0.008 DBMET02227 0.094 0.059 DBMET02229 | DBMET02227 | |
| 0.132 | 0.005 | 0.153 | Potassium channel intermediate-conductance Ca-activated blocker | 0.067 0.03 DBMET02227 0.153 0.004 DBMET02228 0.076 0.02 DBMET02229 | DBMET02228 | |
| 0.22 | 0.095 | 0.22 | Calpain inhibitor | 0.184 0.13 DBMET02227 0.169 0.15 DBMET02228 0.199 0.114 DBMET02229 | ||
| 0.132 | 0.008 | 0.179 | Beta adrenoreceptor antagonist | 0.179 0.004 DBMET02227 0.069 0.04 DBMET02228 0.158 0.005 DBMET02229 | DBMET02227 | |
| 0.145 | 0.021 | 0.263 | Triose-phosphate isomerase inhibitor | 0.137 0.024 DBMET02227 0.263 0.006 DBMET02228 0.155 0.019 DBMET02229 | DBMET02228 | |
| 0.183 | 0.063 | 0.199 | 3C-like protease (Human coronavirus) inhibitor | 0.144 0.111 DBMET02227 0.199 0.052 DBMET02229 | DBMET02229 | |
| 0.13 | 0.012 | 0.13 | Biliverdin reductase inhibitor | 0.1 0.018 DBMET02227 0.067 0.034 DBMET02228 0.114 0.015 DBMET02229 | ||
| 0.146 | 0.029 | 0.177 | CDK3/cyclin E inhibitor | 0.127 0.047 DBMET02227 0.177 0.013 DBMET02228 0.123 0.051 DBMET02229 | DBMET02228 | |
| 0.193 | 0.078 | 0.249 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.249 0.043 DBMET02227 0.176 0.098 DBMET02228 0.186 0.085 DBMET02229 | DBMET02227 | |
| 0.151 | 0.037 | 0.171 | Vanilloid 1 agonist | 0.171 0.023 DBMET02227 0.129 0.069 DBMET02228 0.137 0.055 DBMET02229 | DBMET02227 | |
| 0.242 | 0.128 | 0.297 | Interleukin 2 agonist | 0.297 0.076 DBMET02227 | DBMET02227 | |
| 0.145 | 0.031 | 0.186 | UDP-glucose 4-epimerase inhibitor | 0.159 0.026 DBMET02227 0.158 0.026 DBMET02228 0.186 0.02 DBMET02229 | DBMET02229 | |
| 0.244 | 0.131 | 0.267 | Antithrombotic | 0.267 0.113 DBMET02227 0.209 0.167 DBMET02228 0.215 0.16 DBMET02229 | DBMET02227 | |
| 0.123 | 0.009 | 0.123 | Secretase beta inhibitor | 0.099 0.019 DBMET02227 0.064 0.061 DBMET02229 | ||
| 0.119 | 0.007 | 0.156 | Beta 1 adrenoreceptor antagonist | 0.156 0.005 DBMET02227 0.058 0.038 DBMET02228 0.149 0.005 DBMET02229 | DBMET02227 | |
| 0.13 | 0.018 | 0.226 | Keratolytic | 0.226 0.006 DBMET02227 0.131 0.018 DBMET02228 0.085 0.042 DBMET02229 | DBMET02227 | |
| 0.139 | 0.027 | 0.171 | Prolactin inhibitor | 0.171 0.015 DBMET02227 0.084 0.074 DBMET02228 0.095 0.06 DBMET02229 | DBMET02227 | |
| 0.115 | 0.005 | 0.115 | Sphingosine 1-phosphate receptor 3 antagonist | 0.114 0.005 DBMET02227 0.056 0.045 DBMET02228 0.068 0.028 DBMET02229 | ||
| 0.132 | 0.022 | 0.132 | CYP2A6 inhibitor | 0.076 0.052 DBMET02227 0.074 0.054 DBMET02228 0.077 0.051 DBMET02229 | ||
| 0.12 | 0.01 | 0.12 | Alpha 2 adrenoreceptor agonist | 0.098 0.015 DBMET02227 0.059 0.044 DBMET02229 | ||
| 0.192 | 0.082 | 0.212 | Insulin sensitizer | 0.212 0.062 DBMET02227 0.148 0.136 DBMET02229 | DBMET02227 | |
| 0.195 | 0.087 | 0.291 | Interleukin antagonist | 0.291 0.05 DBMET02227 0.204 0.082 DBMET02228 0.197 0.085 DBMET02229 | DBMET02227 | |
| 0.111 | 0.007 | 0.161 | Beta 2 adrenoreceptor antagonist | 0.161 0.004 DBMET02227 0.052 0.033 DBMET02228 0.132 0.005 DBMET02229 | DBMET02227 | |
| 0.111 | 0.007 | 0.111 | Sphingosine 1-phosphate receptor 5 agonist | 0.085 0.011 DBMET02227 | ||
| 0.132 | 0.029 | 0.151 | Anabolic | 0.151 0.018 DBMET02227 0.11 0.049 DBMET02228 0.13 0.031 DBMET02229 | DBMET02227 | |
| 0.151 | 0.048 | 0.168 | Cyclooxygenase 3 inhibitor | 0.168 0.034 DBMET02227 0.133 0.064 DBMET02229 | DBMET02227 | |
| 0.108 | 0.006 | 0.12 | Sphingosine kinase 2 inhibitor | 0.12 0.005 DBMET02227 0.052 0.044 DBMET02228 | DBMET02227 | |
| 0.127 | 0.025 | 0.127 | Histamine N-methyltransferase inhibitor | 0.119 0.031 DBMET02227 0.083 0.063 DBMET02229 | ||
| 0.14 | 0.038 | 0.167 | Mucolytic | 0.167 0.024 DBMET02227 0.097 0.082 DBMET02229 | DBMET02227 | |
| 0.11 | 0.009 | 0.11 | Bombesin 3 receptor antagonist | 0.083 0.018 DBMET02227 0.065 0.028 DBMET02228 0.094 0.014 DBMET02229 | ||
| 0.137 | 0.036 | 0.193 | Carbonic anhydrase XV inhibitor | 0.193 0.02 DBMET02227 | DBMET02227 | |
| 0.121 | 0.021 | 0.121 | Glutamate release inhibitor | 0.114 0.027 DBMET02227 0.087 0.07 DBMET02229 | ||
| 0.146 | 0.046 | 0.146 | Acetylcholine muscarinic antagonist | 0.143 0.048 DBMET02227 | ||
| 0.115 | 0.016 | 0.115 | Argininosuccinate synthase inhibitor | 0.099 0.019 DBMET02227 0.053 0.043 DBMET02228 0.083 0.024 DBMET02229 | ||
| 0.189 | 0.09 | 0.189 | MAP kinase kinase 2 inhibitor | 0.178 0.097 DBMET02227 | ||
| 0.13 | 0.034 | 0.13 | Acetylcholine release stimulant | 0.1 0.087 DBMET02227 0.128 0.036 DBMET02229 | ||
| 0.13 | 0.034 | 0.243 | Sphingomyelinase inhibitor | 0.11 0.049 DBMET02227 0.243 0.005 DBMET02228 0.1 0.06 DBMET02229 | DBMET02228 | |
| 0.1 | 0.005 | 0.118 | Glutamate (mGluR group III) antagonist | 0.075 0.008 DBMET02227 0.118 0.004 DBMET02228 0.054 0.017 DBMET02229 | DBMET02228 | |
| 0.148 | 0.054 | 0.148 | Cholinergic antagonist | 0.137 0.06 DBMET02227 | ||
| 0.144 | 0.05 | 0.144 | Proteasome inhibitor | 0.136 0.054 DBMET02227 0.119 0.066 DBMET02228 0.125 0.061 DBMET02229 | ||
| 0.112 | 0.019 | 0.136 | GABA aminotransferase inhibitor | 0.136 0.011 DBMET02227 0.075 0.053 DBMET02228 0.081 0.045 DBMET02229 | DBMET02227 | |
| 0.102 | 0.01 | 0.102 | Glutamate (mGluR7) antagonist | 0.095 0.014 DBMET02227 0.065 0.053 DBMET02228 0.076 0.033 DBMET02229 | ||
| 0.145 | 0.053 | 0.145 | Acetylcholine antagonist | 0.134 0.059 DBMET02227 | ||
| 0.116 | 0.024 | 0.116 | Glutamate dehydrogenase inhibitor | 0.114 0.025 DBMET02227 0.069 0.058 DBMET02228 0.088 0.038 DBMET02229 | ||
| 0.138 | 0.046 | 0.246 | Cystathionine beta-synthase inhibitor | 0.246 0.016 DBMET02227 0.099 0.078 DBMET02229 | DBMET02227 | |
| 0.198 | 0.106 | 0.368 | Vasodilator | 0.24 0.075 DBMET02227 0.368 0.029 DBMET02229 | DBMET02229 | |
| 0.112 | 0.021 | 0.112 | Granulocyte macrophage colony stimulating factor agonist | 0.109 0.024 DBMET02227 0.085 0.061 DBMET02228 0.091 0.05 DBMET02229 | ||
| 0.108 | 0.017 | 0.142 | Estrogen-related receptor beta agonist | 0.142 0.005 DBMET02227 0.096 0.03 DBMET02228 0.1 0.025 DBMET02229 | DBMET02227 | |
| 0.135 | 0.045 | 0.135 | Falcipain 3 inhibitor | 0.116 0.056 DBMET02227 | ||
| 0.127 | 0.037 | 0.187 | Potassium channel (Ca-activated) activator | 0.187 0.017 DBMET02227 0.079 0.077 DBMET02228 0.088 0.067 DBMET02229 | DBMET02227 | |
| 0.167 | 0.077 | 0.167 | Antipruritic | 0.161 0.082 DBMET02227 | ||
| 0.12 | 0.031 | 0.12 | Lanosterol 14 alpha demethylase inhibitor | 0.115 0.036 DBMET02227 0.096 0.061 DBMET02228 0.113 0.038 DBMET02229 | ||
| 0.203 | 0.114 | 0.203 | Neuropeptide Y2 antagonist | 0.199 0.121 DBMET02227 | ||
| 0.106 | 0.017 | 0.106 | Adrenaline uptake inhibitor | 0.062 0.043 DBMET02227 | ||
| 0.092 | 0.005 | 0.129 | Beta 2 adrenoreceptor agonist | 0.129 0.003 DBMET02227 0.062 0.043 DBMET02228 0.066 0.03 DBMET02229 | DBMET02227 | |
| 0.1 | 0.013 | 0.105 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.078 0.041 DBMET02227 0.105 0.011 DBMET02228 0.083 0.032 DBMET02229 | DBMET02228 | |
| 0.186 | 0.099 | 0.186 | HERG channel blocker | |||
| 0.105 | 0.019 | 0.106 | Sphingosine 1-phosphate receptor antagonist | 0.106 0.018 DBMET02227 0.085 0.036 DBMET02229 | DBMET02227 | |
| 0.091 | 0.005 | 0.15 | Dopamine D5 agonist | 0.15 0.003 DBMET02227 0.054 0.015 DBMET02228 0.055 0.014 DBMET02229 | DBMET02227 | |
| 0.157 | 0.072 | 0.231 | Melanin inhibitor | 0.231 0.032 DBMET02227 0.172 0.057 DBMET02228 0.145 0.088 DBMET02229 | DBMET02227 | |
| 0.109 | 0.024 | 0.109 | Nicotinic alpha4beta2 receptor antagonist | 0.07 0.062 DBMET02227 0.094 0.037 DBMET02229 | ||
| 0.094 | 0.009 | 0.106 | Sphingosine kinase inhibitor | 0.106 0.006 DBMET02227 | DBMET02227 | |
| 0.106 | 0.023 | 0.134 | D-Ala-D-Ala ligase inhibitor | 0.134 0.009 DBMET02227 0.082 0.063 DBMET02228 0.098 0.032 DBMET02229 | DBMET02227 | |
| 0.138 | 0.056 | 0.138 | Nav1.3 sodium channel blocker | |||
| 0.099 | 0.017 | 0.099 | Acyl-CoA dehydrogenase inhibitor | 0.075 0.024 DBMET02227 0.051 0.041 DBMET02228 0.058 0.034 DBMET02229 | ||
| 0.129 | 0.048 | 0.129 | 5 Hydroxytryptamine 3A agonist | 0.11 0.065 DBMET02227 | ||
| 0.101 | 0.021 | 0.101 | Glucagon-like peptide 1 agonist | 0.096 0.024 DBMET02227 0.066 0.044 DBMET02229 | ||
| 0.271 | 0.19 | 0.337 | Cyclophilin D inhibitor | 0.337 0.133 DBMET02227 | DBMET02227 | |
| 0.197 | 0.118 | 0.207 | DNA damaging | 0.207 0.11 DBMET02227 0.184 0.13 DBMET02229 | DBMET02227 | |
| 0.096 | 0.017 | 0.096 | Ornithine carbamoyltransferase inhibitor | 0.079 0.022 DBMET02227 0.058 0.033 DBMET02229 | ||
| 0.113 | 0.033 | 0.122 | NADH dehydrogenase inhibitor | 0.122 0.027 DBMET02227 0.087 0.062 DBMET02228 0.091 0.055 DBMET02229 | DBMET02227 | |
| 0.082 | 0.004 | 0.082 | Glutamate (mGluR8) agonist | 0.077 0.004 DBMET02227 0.043 0.018 DBMET02228 0.06 0.007 DBMET02229 | ||
| 0.085 | 0.008 | 0.085 | Bombesin antagonist | 0.065 0.015 DBMET02227 0.07 0.013 DBMET02228 0.075 0.011 DBMET02229 | ||
| 0.148 | 0.071 | 0.175 | Thiol protease inhibitor | 0.123 0.111 DBMET02227 0.175 0.051 DBMET02229 | DBMET02229 | |
| 0.127 | 0.05 | 0.129 | Photosensitizer | 0.129 0.047 DBMET02227 0.1 0.089 DBMET02228 0.111 0.07 DBMET02229 | DBMET02227 | |
| 0.2 | 0.123 | 0.2 | MAP kinase kinase 3 inhibitor | |||
| 0.086 | 0.012 | 0.086 | Aconitate hydratase inhibitor | 0.067 0.02 DBMET02227 0.056 0.031 DBMET02228 0.06 0.026 DBMET02229 | ||
| 0.093 | 0.019 | 0.093 | Protease 3C (Human rhinovirus) inhibitor | 0.075 0.031 DBMET02227 0.069 0.038 DBMET02229 | ||
| 0.098 | 0.024 | 0.107 | CC chemokine 5 receptor agonist | 0.107 0.016 DBMET02227 0.081 0.06 DBMET02228 0.093 0.032 DBMET02229 | DBMET02227 | |
| 0.083 | 0.01 | 0.083 | Aldosterone antagonist | 0.048 0.031 DBMET02227 0.054 0.024 DBMET02229 | ||
| 0.142 | 0.069 | 0.146 | Pregnane X receptor agonist | 0.133 0.09 DBMET02227 0.146 0.06 DBMET02229 | DBMET02229 | |
| 0.102 | 0.03 | 0.105 | Glycine receptor antagonist | 0.081 0.055 DBMET02227 0.095 0.037 DBMET02228 0.105 0.028 DBMET02229 | DBMET02229 | |
| 0.093 | 0.022 | 0.114 | GABA B receptor agonist | 0.114 0.009 DBMET02227 0.079 0.045 DBMET02228 0.08 0.042 DBMET02229 | DBMET02227 | |
| 0.114 | 0.045 | 0.114 | Factor V inhibitor | 0.098 0.074 DBMET02227 0.096 0.078 DBMET02229 | ||
| 0.169 | 0.101 | 0.261 | Pyruvate kinase inhibitor | 0.261 0.058 DBMET02227 | DBMET02227 | |
| 0.075 | 0.008 | 0.12 | Immunoglobulin Fc receptor antagonist | 0.068 0.013 DBMET02227 0.12 0.003 DBMET02228 0.061 0.023 DBMET02229 | DBMET02228 | |
| 0.118 | 0.052 | 0.156 | Expectorant | 0.156 0.033 DBMET02227 | DBMET02227 | |
| 0.084 | 0.02 | 0.084 | Exportin-1 inhibitor | 0.072 0.039 DBMET02229 | ||
| 0.076 | 0.013 | 0.076 | Alpha-mannosidase inhibitor | 0.076 0.013 DBMET02227 0.051 0.042 DBMET02228 0.057 0.031 DBMET02229 | ||
| 0.09 | 0.028 | 0.09 | Glycine receptor agonist | 0.09 0.028 DBMET02227 0.07 0.056 DBMET02228 | ||
| 0.109 | 0.047 | 0.109 | Electrolyte absorption antagonist | 0.085 0.083 DBMET02227 | ||
| 0.069 | 0.007 | 0.069 | Diamine oxidase inhibitor | 0.043 0.02 DBMET02227 0.045 0.018 DBMET02228 0.034 0.031 DBMET02229 | ||
| 0.076 | 0.015 | 0.094 | Nicotinic alpha3beta2 receptor antagonist | 0.052 0.039 DBMET02227 0.057 0.031 DBMET02228 0.094 0.009 DBMET02229 | DBMET02229 | |
| 0.076 | 0.015 | 0.077 | Sphingosine 1-phosphate receptor 1 antagonist | 0.077 0.015 DBMET02227 0.058 0.033 DBMET02229 | DBMET02227 | |
| 0.092 | 0.031 | 0.092 | Alpha adrenoreceptor agonist | 0.08 0.038 DBMET02227 | ||
| 0.09 | 0.029 | 0.09 | Neuropeptide agonist | 0.078 0.032 DBMET02227 | ||
| 0.079 | 0.019 | 0.079 | Gonadotropin-releasing hormone receptor agonist | 0.076 0.02 DBMET02227 0.061 0.038 DBMET02229 | ||
| 0.236 | 0.177 | 0.357 | 15-Lipoxygenase inhibitor | 0.357 0.095 DBMET02227 0.3 0.132 DBMET02229 | DBMET02227 | |
| 0.119 | 0.06 | 0.149 | TRPA1 agonist | 0.133 0.044 DBMET02227 0.149 0.032 DBMET02229 | DBMET02229 | |
| 0.063 | 0.007 | 0.063 | Glutamate (mGluR3) antagonist | 0.058 0.009 DBMET02227 0.038 0.023 DBMET02228 0.033 0.032 DBMET02229 | ||
| 0.081 | 0.025 | 0.081 | Bombesin 1 receptor agonist | 0.065 0.035 DBMET02227 | ||
| 0.067 | 0.011 | 0.067 | Histamine H2 receptor agonist | 0.058 0.016 DBMET02229 | ||
| 0.068 | 0.013 | 0.068 | Mannosidase inhibitor | 0.067 0.013 DBMET02227 0.045 0.032 DBMET02229 | ||
| 0.062 | 0.006 | 0.062 | Dipeptidyl peptidase II inhibitor | 0.033 0.022 DBMET02227 0.046 0.011 DBMET02228 | ||
| 0.063 | 0.008 | 0.063 | Glucagon-like peptide 1 receptor antagonist | 0.048 0.015 DBMET02227 0.038 0.031 DBMET02228 0.053 0.012 DBMET02229 | ||
| 0.062 | 0.007 | 0.093 | Beta adrenoreceptor agonist | 0.093 0.004 DBMET02227 0.066 0.006 DBMET02229 | DBMET02227 | |
| 0.071 | 0.017 | 0.071 | Dipeptidyl peptidase inhibitor | |||
| 0.064 | 0.009 | 0.068 | Arginase inhibitor | 0.068 0.008 DBMET02227 0.053 0.013 DBMET02228 | DBMET02227 | |
| 0.071 | 0.017 | 0.071 | Epithelial sodium channel blocker | 0.066 0.021 DBMET02227 | ||
| 0.079 | 0.026 | 0.079 | Carbonic anhydrase stimulant | 0.061 0.039 DBMET02227 | ||
| 0.071 | 0.019 | 0.071 | Bombesin 2 receptor antagonist | 0.067 0.021 DBMET02227 0.063 0.023 DBMET02228 0.057 0.026 DBMET02229 | ||
| 0.06 | 0.009 | 0.062 | Sphingosine kinase 1 inhibitor | 0.062 0.008 DBMET02227 | DBMET02227 | |
| 0.058 | 0.008 | 0.058 | Kainate receptor agonist | 0.055 0.009 DBMET02227 0.045 0.021 DBMET02228 0.048 0.016 DBMET02229 | ||
| 0.059 | 0.009 | 0.059 | Histamine H1 receptor agonist | 0.042 0.034 DBMET02229 | ||
| 0.062 | 0.012 | 0.062 | Sphingosine 1-phosphate receptor 1 agonist | 0.056 0.015 DBMET02227 | ||
| 0.061 | 0.012 | 0.061 | Cytokine production stimulant | 0.049 0.032 DBMET02227 0.057 0.016 DBMET02228 0.045 0.043 DBMET02229 | ||
| 0.123 | 0.074 | 0.179 | Toll-Like receptor 2 antagonist | 0.179 0.035 DBMET02227 | DBMET02227 | |
| 0.076 | 0.028 | 0.092 | Acetylcholine M3 receptor antagonist | 0.092 0.021 DBMET02227 | DBMET02227 | |
| 0.107 | 0.059 | 0.107 | Protease inhibitor | 0.09 0.074 DBMET02227 | ||
| 0.075 | 0.028 | 0.092 | Purinergic P2X1 antagonist | 0.092 0.019 DBMET02227 0.055 0.052 DBMET02228 0.074 0.029 DBMET02229 | DBMET02227 | |
| 0.071 | 0.025 | 0.073 | Calcium channel P-type blocker | 0.061 0.056 DBMET02227 0.073 0.023 DBMET02229 | DBMET02229 | |
| 0.061 | 0.014 | 0.071 | Dopamine beta hydroxylase inhibitor | 0.071 0.008 DBMET02227 0.06 0.015 DBMET02228 | DBMET02227 | |
| 0.077 | 0.031 | 0.077 | NMDA receptor agonist | 0.065 0.041 DBMET02227 0.076 0.032 DBMET02228 0.061 0.046 DBMET02229 | ||
| 0.139 | 0.094 | 0.168 | Interferon gamma antagonist | 0.168 0.059 DBMET02227 0.13 0.11 DBMET02229 | DBMET02227 | |
| 0.103 | 0.058 | 0.166 | Carbonic anhydrase III inhibitor | 0.166 0.023 DBMET02227 0.13 0.038 DBMET02228 0.09 0.075 DBMET02229 | DBMET02227 | |
| 0.115 | 0.07 | 0.122 | Transcription factor STAT6 inhibitor | 0.122 0.057 DBMET02227 | DBMET02227 | |
| 0.088 | 0.043 | 0.088 | Catalase inhibitor | 0.083 0.046 DBMET02227 | ||
| 0.119 | 0.075 | 0.172 | MAO inhibitor | 0.172 0.051 DBMET02227 | DBMET02227 | |
| 0.06 | 0.016 | 0.06 | Sphingosine 1-phosphate receptor agonist | 0.054 0.022 DBMET02227 | ||
| 0.079 | 0.036 | 0.079 | Phospholipase D inhibitor | 0.066 0.062 DBMET02229 | ||
| 0.129 | 0.087 | 0.151 | Mannose-6-phosphate isomerase inhibitor | 0.122 0.097 DBMET02227 0.138 0.076 DBMET02228 0.151 0.064 DBMET02229 | DBMET02229 | |
| 0.058 | 0.015 | 0.058 | Geranyltranstransferase inhibitor | 0.051 0.021 DBMET02227 0.04 0.038 DBMET02229 | ||
| 0.082 | 0.04 | 0.104 | MAP kinase kinase 7 inhibitor | 0.104 0.01 DBMET02227 | DBMET02227 | |
| 0.089 | 0.047 | 0.142 | Carbonic anhydrase VI inhibitor | 0.142 0.023 DBMET02227 0.071 0.07 DBMET02228 | DBMET02227 | |
| 0.053 | 0.012 | 0.065 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.065 0.005 DBMET02227 0.044 0.024 DBMET02228 0.045 0.022 DBMET02229 | DBMET02227 | |
| 0.135 | 0.095 | 0.145 | Heat shock protein 70 antagonist | 0.145 0.058 DBMET02227 | DBMET02227 | |
| 0.052 | 0.013 | 0.061 | Fumarate hydratase inhibitor | 0.045 0.016 DBMET02227 0.03 0.029 DBMET02228 0.061 0.01 DBMET02229 | DBMET02229 | |
| 0.055 | 0.016 | 0.055 | Dipeptidyl peptidase IV inhibitor | |||
| 0.048 | 0.009 | 0.048 | Glutamate (mGluR8) antagonist | 0.043 0.013 DBMET02227 | ||
| 0.063 | 0.024 | 0.063 | Pregnane X receptor antagonist | 0.062 0.026 DBMET02227 0.054 0.046 DBMET02228 0.063 0.025 DBMET02229 | ||
| 0.068 | 0.029 | 0.083 | Carbonic anhydrase VB inhibitor | 0.083 0.021 DBMET02227 0.053 0.042 DBMET02228 | DBMET02227 | |
| 0.068 | 0.03 | 0.068 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.055 | 0.017 | 0.055 | Guanylate cyclase stimulant | |||
| 0.044 | 0.007 | 0.053 | Glutamate (mGluR3) agonist | 0.053 0.004 DBMET02227 0.032 0.024 DBMET02228 | DBMET02227 | |
| 0.079 | 0.044 | 0.079 | Cathepsin G inhibitor | 0.076 0.047 DBMET02227 | ||
| 0.05 | 0.015 | 0.053 | Vascular adhesion protein 1 inhibitor | 0.053 0.013 DBMET02228 | DBMET02228 | |
| 0.064 | 0.031 | 0.064 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.054 0.042 DBMET02227 0.05 0.048 DBMET02229 | ||
| 0.109 | 0.076 | 0.109 | Microtubule formation inhibitor | 0.107 0.078 DBMET02227 | ||
| 0.073 | 0.041 | 0.074 | Protein kinase C beta inhibitor | 0.074 0.041 DBMET02227 | DBMET02227 | |
| 0.109 | 0.077 | 0.13 | Interleukin 8 antagonist | 0.119 0.062 DBMET02227 0.13 0.05 DBMET02229 | DBMET02229 | |
| 0.061 | 0.03 | 0.061 | Protein kinase C epsilon inhibitor | |||
| 0.098 | 0.066 | 0.143 | MAO A inhibitor | 0.143 0.043 DBMET02227 | DBMET02227 | |
| 0.069 | 0.037 | 0.077 | NMDA receptor glycine site agonist | 0.077 0.03 DBMET02228 0.064 0.042 DBMET02229 | DBMET02228 | |
| 0.057 | 0.026 | 0.06 | Lysophosphatidic acid 3 receptor antagonist | 0.049 0.038 DBMET02227 0.047 0.041 DBMET02228 0.06 0.022 DBMET02229 | DBMET02229 | |
| 0.046 | 0.016 | 0.082 | Potassium channel Kv1.1 blocker | 0.082 0.005 DBMET02229 | DBMET02229 | |
| 0.042 | 0.012 | 0.042 | Tryptophan 5 hydroxylase inhibitor | 0.033 0.032 DBMET02227 | ||
| 0.038 | 0.008 | 0.048 | Purinergic P2Y15 antagonist | 0.034 0.011 DBMET02227 0.048 0.004 DBMET02228 0.028 0.02 DBMET02229 | DBMET02228 | |
| 0.053 | 0.023 | 0.087 | Adenylate cyclase 1 inhibitor | 0.048 0.028 DBMET02227 0.087 0.005 DBMET02228 | DBMET02228 | |
| 0.052 | 0.022 | 0.062 | Oxytocin agonist | 0.062 0.015 DBMET02227 | DBMET02227 | |
| 0.05 | 0.021 | 0.105 | Glutamate (mGluR4) antagonist | 0.04 0.037 DBMET02227 0.105 0.005 DBMET02228 0.045 0.027 DBMET02229 | DBMET02228 | |
| 0.123 | 0.095 | 0.139 | Cell wall synthesis inhibitor | 0.139 0.076 DBMET02227 0.115 0.108 DBMET02228 0.118 0.102 DBMET02229 | DBMET02227 | |
| 0.041 | 0.013 | 0.041 | Growth factor receptor-bound protein 2 antagonist | 0.039 0.016 DBMET02227 0.035 0.025 DBMET02229 | ||
| 0.054 | 0.026 | 0.054 | Melanocortin antagonist | |||
| 0.05 | 0.023 | 0.05 | Liver X receptor agonist | 0.047 0.025 DBMET02227 | ||
| 0.034 | 0.006 | 0.035 | Vanilloid 2 agonist | 0.035 0.005 DBMET02227 0.025 0.018 DBMET02228 0.028 0.012 DBMET02229 | DBMET02227 | |
| 0.034 | 0.007 | 0.034 | Glutamate (mGluR1a) agonist | 0.024 0.013 DBMET02227 | ||
| 0.05 | 0.023 | 0.05 | Glutamate (mGluR group III) agonist | |||
| 0.033 | 0.007 | 0.056 | Beta 1 adrenoreceptor agonist | 0.056 0.004 DBMET02227 | DBMET02227 | |
| 0.066 | 0.041 | 0.066 | 5 Hydroxytryptamine 2A agonist | 0.061 0.046 DBMET02227 | ||
| 0.066 | 0.041 | 0.066 | Interferon inducer | |||
| 0.053 | 0.028 | 0.053 | Adenosine deaminase inhibitor | 0.051 0.029 DBMET02227 0.044 0.036 DBMET02228 | ||
| 0.107 | 0.082 | 0.107 | Calcium channel N-type blocker | |||
| 0.059 | 0.035 | 0.075 | Protein kinase C eta inhibitor | 0.075 0.026 DBMET02227 | DBMET02227 | |
| 0.063 | 0.04 | 0.063 | Histone deacetylase SIRT3 inhibitor | |||
| 0.032 | 0.009 | 0.032 | Follicle-stimulating hormone agonist | |||
| 0.078 | 0.055 | 0.078 | Interferon agonist | |||
| 0.076 | 0.054 | 0.087 | Na+ K+ transporting ATPase inhibitor | 0.087 0.044 DBMET02227 0.068 0.062 DBMET02228 0.079 0.052 DBMET02229 | DBMET02227 | |
| 0.068 | 0.045 | 0.07 | MDM2 inhibitor | 0.07 0.038 DBMET02229 | DBMET02229 | |
| 0.043 | 0.021 | 0.043 | Cholecystokinin B agonist | 0.038 0.025 DBMET02227 | ||
| 0.078 | 0.057 | 0.078 | Acetylcholine nicotinic antagonist | |||
| 0.062 | 0.042 | 0.076 | NMDA 2C receptor antagonist | 0.076 0.028 DBMET02227 | DBMET02227 | |
| 0.204 | 0.184 | 0.228 | Calpain 2 inhibitor | 0.228 0.166 DBMET02229 | DBMET02229 | |
| 0.034 | 0.014 | 0.034 | Melanocortin 5 antagonist | |||
| 0.047 | 0.027 | 0.053 | Nicotinic receptor alpha3 subunit antagonist | 0.053 0.023 DBMET02229 | DBMET02229 | |
| 0.087 | 0.068 | 0.087 | Polo-like kinase-1 inhibitor | |||
| 0.042 | 0.023 | 0.042 | Glutamate (mGluR group II) antagonist | |||
| 0.049 | 0.031 | 0.081 | Glucose-6-phosphate isomerase inhibitor | 0.048 0.032 DBMET02227 0.081 0.008 DBMET02228 0.048 0.032 DBMET02229 | DBMET02228 | |
| 0.042 | 0.024 | 0.042 | Substance P antagonist | |||
| 0.036 | 0.018 | 0.036 | Carboxypeptidase B inhibitor | 0.032 0.024 DBMET02227 0.031 0.028 DBMET02228 | ||
| 0.026 | 0.008 | 0.026 | Guanylate cyclase 1 stimulant | |||
| 0.028 | 0.011 | 0.028 | Complement factor 1s inhibitor | |||
| 0.067 | 0.05 | 0.08 | Carbonic anhydrase VA inhibitor | 0.08 0.037 DBMET02227 0.067 0.05 DBMET02228 | DBMET02227 | |
| 0.021 | 0.004 | 0.022 | Glutamate (mGluR6) agonist | 0.022 0.004 DBMET02227 0.013 0.008 DBMET02229 | DBMET02227 | |
| 0.028 | 0.011 | 0.028 | Glutamate (mGluR1) agonist | 0.024 0.019 DBMET02227 | ||
| 0.041 | 0.024 | 0.041 | 5 Hydroxytryptamine 2B agonist | |||
| 0.039 | 0.023 | 0.041 | Kinesin antagonist | 0.041 0.021 DBMET02227 | DBMET02227 | |
| 0.039 | 0.023 | 0.041 | Kinesin-like protein 1 inhibitor | 0.041 0.021 DBMET02227 | DBMET02227 | |
| 0.186 | 0.17 | 0.253 | Hypoxia-inducible factor 1 alpha inhibitor | 0.253 0.097 DBMET02227 0.195 0.158 DBMET02229 | DBMET02227 | |
| 0.057 | 0.041 | 0.058 | Cathepsin L inhibitor | 0.058 0.04 DBMET02229 | DBMET02229 | |
| 0.072 | 0.056 | 0.12 | Carbonic anhydrase XIII inhibitor | 0.12 0.03 DBMET02227 | DBMET02227 | |
| 0.024 | 0.009 | 0.025 | Neuraminidase (Influenza B) inhibitor | 0.025 0.008 DBMET02227 | DBMET02227 | |
| 0.126 | 0.11 | 0.128 | Neuropeptide Y1 antagonist | 0.128 0.104 DBMET02227 | DBMET02227 | |
| 0.057 | 0.041 | 0.057 | Dopamine uptake inhibitor | |||
| 0.081 | 0.065 | 0.097 | Myeloperoxidase inhibitor | 0.09 0.049 DBMET02227 0.097 0.039 DBMET02228 | DBMET02228 | |
| 0.065 | 0.05 | 0.065 | Potassium channel (ATP-sensitive) blocker | 0.061 0.059 DBMET02227 | ||
| 0.041 | 0.026 | 0.046 | Membrane dipeptidase inhibitor | 0.046 0.019 DBMET02228 | DBMET02228 | |
| 0.072 | 0.058 | 0.078 | Vanilloid 4 agonist | 0.078 0.045 DBMET02229 | DBMET02229 | |
| 0.023 | 0.009 | 0.038 | Aminopeptidase A inhibitor | 0.021 0.01 DBMET02227 0.038 0.005 DBMET02228 | DBMET02228 | |
| 0.028 | 0.013 | 0.028 | Lysophosphatidic acid receptor 1 agonist | 0.023 0.022 DBMET02228 0.024 0.019 DBMET02229 | ||
| 0.028 | 0.013 | 0.028 | Acid ceramidase inhibitor | 0.028 0.012 DBMET02229 | ||
| 0.023 | 0.009 | 0.023 | Toll-Like receptor 8 agonist | |||
| 0.05 | 0.036 | 0.05 | Diacylglycerol O-acyltransferase inhibitor | |||
| 0.025 | 0.011 | 0.025 | Isoleucine-tRNA ligase inhibitor | 0.024 0.013 DBMET02227 | ||
| 0.094 | 0.081 | 0.203 | Monophenol monooxygenase inhibitor | 0.203 0.033 DBMET02227 0.124 0.059 DBMET02228 | DBMET02227 | |
| 0.032 | 0.019 | 0.032 | Epoxide hydrolase 1 inhibitor | 0.031 0.021 DBMET02229 | ||
| 0.039 | 0.027 | 0.039 | Alpha 1d adrenoreceptor agonist | |||
| 0.051 | 0.039 | 0.051 | Histamine agonist | |||
| 0.039 | 0.028 | 0.039 | AMPA 4 receptor antagonist | 0.039 0.028 DBMET02227 | ||
| 0.034 | 0.023 | 0.034 | Glutamate (mGluR4) agonist | |||
| 0.028 | 0.017 | 0.028 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.028 0.018 DBMET02227 | ||
| 0.042 | 0.032 | 0.045 | Heme oxygenase inhibitor | 0.045 0.022 DBMET02229 | DBMET02229 | |
| 0.023 | 0.012 | 0.023 | Imidazoline I1 receptor antagonist | |||
| 0.041 | 0.031 | 0.041 | Angiotensin AT1 receptor antagonist | |||
| 0.049 | 0.038 | 0.055 | Potassium channel (Inward rectifier) activator | 0.055 0.026 DBMET02229 | DBMET02229 | |
| 0.037 | 0.027 | 0.037 | Melanocortin 1 antagonist | |||
| 0.04 | 0.03 | 0.04 | Glutamate (mGluR1a) antagonist | |||
| 0.049 | 0.039 | 0.074 | NMDA 2A receptor antagonist | 0.074 0.022 DBMET02227 | DBMET02227 | |
| 0.031 | 0.021 | 0.031 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.028 | 0.019 | 0.028 | Uridine phosphorylase inhibitor | 0.024 0.023 DBMET02227 | ||
| 0.113 | 0.103 | 0.144 | Papain-like protease (SARS coronavirus) inhibitor | 0.144 0.04 DBMET02227 | DBMET02227 | |
| 0.038 | 0.029 | 0.038 | GABA uptake inhibitor | |||
| 0.046 | 0.037 | 0.052 | Potassium channel (ATP-sensitive) activator | 0.052 0.025 DBMET02229 | DBMET02229 | |
| 0.061 | 0.053 | 0.077 | Carbonic anhydrase V inhibitor | 0.077 0.038 DBMET02227 0.064 0.048 DBMET02228 | DBMET02227 | |
| 0.078 | 0.07 | 0.082 | Histamine H2 receptor antagonist | 0.082 0.061 DBMET02229 | DBMET02229 | |
| 0.037 | 0.03 | 0.039 | Cathepsin L1 inhibitor | 0.039 0.028 DBMET02229 | DBMET02229 | |
| 0.036 | 0.029 | 0.036 | Delayed rectifier potassium channel blocker | |||
| 0.052 | 0.046 | 0.078 | Dihydroorotate oxidase inhibitor | 0.056 0.035 DBMET02227 0.078 0.011 DBMET02228 0.053 0.041 DBMET02229 | DBMET02228 | |
| 0.033 | 0.027 | 0.033 | Angiotensin II receptor antagonist | |||
| 0.018 | 0.012 | 0.027 | Nicotinic acid receptor 1 antagonist | 0.027 0.005 DBMET02227 | DBMET02227 | |
| 0.06 | 0.055 | 0.075 | Acetylcholine M5 receptor agonist | 0.075 0.039 DBMET02229 | DBMET02229 | |
| 0.039 | 0.033 | 0.039 | Plasmepsin II inhibitor | |||
| 0.034 | 0.028 | 0.034 | Ceramide glucosyltransferase inhibitor | 0.034 0.029 DBMET02227 | ||
| 0.128 | 0.123 | 0.128 | LIM domain kinase 1 inhibitor | |||
| 0.025 | 0.021 | 0.025 | Nicotinic acid receptor 2 antagonist | |||
| 0.016 | 0.012 | 0.016 | Carbonic anhydrase VIII inhibitor | |||
| 0.016 | 0.012 | 0.016 | Carbonic anhydrase X inhibitor | |||
| 0.025 | 0.021 | 0.031 | Sodium/glucose cotransporter 2 inhibitor | 0.031 0.012 DBMET02227 | DBMET02227 | |
| 0.026 | 0.023 | 0.026 | Hedgehog signaling activator | |||
| 0.017 | 0.013 | 0.018 | Telomerase stimulant | 0.018 0.011 DBMET02227 | DBMET02227 | |
| 0.015 | 0.011 | 0.016 | NMDA receptor phencyclidine site antagonist | 0.016 0.01 DBMET02227 | DBMET02227 | |
| 0.057 | 0.054 | 0.057 | 5 Hydroxytryptamine 3 agonist | |||
| 0.033 | 0.03 | 0.033 | Adenosine uptake inhibitor | |||
| 0.045 | 0.042 | 0.045 | Neurokinin antagonist | |||
| 0.024 | 0.022 | 0.028 | Sodium/glucose cotransporter inhibitor | 0.028 0.013 DBMET02227 | DBMET02227 | |
| 0.018 | 0.015 | 0.027 | Estrogen-related receptor gamma agonist | 0.027 0.005 DBMET02227 | DBMET02227 | |
| 0.061 | 0.059 | 0.107 | Potassium channel large-conductance Ca-activated activator | 0.107 0.021 DBMET02227 | DBMET02227 | |
| 0.033 | 0.031 | 0.033 | Nicotinic receptor beta4 subunit antagonist | |||
| 0.093 | 0.091 | 0.166 | Adenylate cyclase inhibitor | 0.119 0.068 DBMET02227 0.166 0.035 DBMET02228 | DBMET02228 | |
| 0.067 | 0.066 | 0.067 | Glutamate receptor agonist | |||
| 0.026 | 0.025 | 0.035 | Estrogen-related receptor gamma antagonist | 0.035 0.008 DBMET02227 0.028 0.022 DBMET02229 | DBMET02227 | |
| 0.024 | 0.023 | 0.024 | Lysine carboxypeptidase inhibitor | |||
| 0.063 | 0.063 | 0.074 | Calcium channel L-type blocker | 0.074 0.047 DBMET02229 | DBMET02229 | |
| 0.031 | 0.031 | 0.033 | Phosphoglycerate kinase inhibitor | 0.033 0.027 DBMET02227 | DBMET02227 | |
| 0.152 | 0.153 | 0.198 | Immunostimulant | 0.198 0.122 DBMET02227 | DBMET02227 | |
| 0.078 | 0.079 | 0.091 | Potassium channel activator | 0.091 0.059 DBMET02229 | DBMET02229 | |
| 0.085 | 0.086 | 0.1 | Bile acid receptor antagonist | 0.1 0.049 DBMET02227 | DBMET02227 | |
| 0.028 | 0.029 | 0.031 | Calcitonin receptor agonist | 0.031 0.026 DBMET02227 | DBMET02227 | |
| 0.038 | 0.04 | 0.056 | Glycine transporter 2 inhibitor | 0.056 0.027 DBMET02227 | DBMET02227 | |
| 0.036 | 0.038 | 0.038 | Growth hormone release inhibitor | 0.038 0.034 DBMET02227 | DBMET02227 | |
| 0.011 | 0.014 | 0.029 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.029 0.003 DBMET02228 | DBMET02228 | |
| 0.067 | 0.07 | 0.093 | Somatostatin 1 agonist | 0.093 0.039 DBMET02227 | DBMET02227 | |
| 0.017 | 0.021 | 0.02 | Antibiotic Anthracycline-like | 0.02 0.011 DBMET02227 | DBMET02227 | |
| 0.083 | 0.087 | 0.147 | Urease inhibitor | 0.103 0.063 DBMET02227 0.147 0.024 DBMET02228 | DBMET02228 | |
| 0.037 | 0.042 | 0.039 | HIV-1 protease inhibitor | 0.039 0.037 DBMET02227 | DBMET02227 | |
| 0.03 | 0.035 | 0.049 | Inosine monophosphate dehydrogenase inhibitor | 0.049 0.015 DBMET02228 | DBMET02228 | |
| 0.105 | 0.112 | 0.147 | Protein kinase stimulant | 0.147 0.07 DBMET02227 | DBMET02227 | |
| 0.035 | 0.042 | 0.06 | NMDA receptor subunit 3B antagonist | 0.06 0.019 DBMET02227 | DBMET02227 | |
| 0.026 | 0.035 | 0.029 | Methionyl aminopeptidase 1 inhibitor | 0.029 0.028 DBMET02228 | DBMET02228 | |
| 0.12 | 0.128 | 0.181 | Heat shock protein 90 alpha antagonist | 0.181 0.062 DBMET02227 0.124 0.121 DBMET02229 | DBMET02227 | |
| 0.073 | 0.082 | 0.105 | MAO B inhibitor | 0.105 0.057 DBMET02227 | DBMET02227 | |
| 0.032 | 0.041 | 0.04 | Dihydropteroate synthase inhibitor | 0.04 0.027 DBMET02227 | DBMET02227 | |
| 0.051 | 0.06 | 0.053 | Leukotriene C antagonist | 0.053 0.049 DBMET02227 | DBMET02227 | |
| 0.037 | 0.047 | 0.05 | Fructose-1,6-bisphosphatase inhibitor | 0.05 0.025 DBMET02229 | DBMET02229 | |
| 0.102 | 0.113 | 0.124 | Calcium channel blocker | 0.124 0.083 DBMET02229 | DBMET02229 | |
| 0.044 | 0.055 | 0.23 | Aminopeptidase microsomal inhibitor | 0.23 0.004 DBMET02228 | DBMET02228 | |
| 0.006 | 0.018 | 0.012 | Beta 3 adrenoreceptor agonist | 0.012 0.007 DBMET02227 | DBMET02227 | |
| 0.05 | 0.062 | 0.077 | Heat shock protein 90 beta antagonist | 0.077 0.023 DBMET02227 | DBMET02227 | |
| 0.024 | 0.036 | 0.03 | 1,3-Beta-glucan synthase inhibitor | 0.03 0.016 DBMET02227 | DBMET02227 | |
| 0.027 | 0.04 | 0.052 | NMDA receptor subunit 3A antagonist | 0.052 0.019 DBMET02227 | DBMET02227 | |
| 0.051 | 0.063 | 0.118 | Neutrophil collagenase inhibitor | 0.118 0.017 DBMET02228 | DBMET02228 | |
| 0.046 | 0.059 | 0.13 | Opioid delta receptor antagonist | 0.13 0.023 DBMET02227 | DBMET02227 | |
| 0.113 | 0.126 | 0.134 | Phospholipase A2 inhibitor | 0.134 0.095 DBMET02227 | DBMET02227 | |
| 0.09 | 0.103 | 0.116 | Cholesterol synthesis inhibitor | 0.116 0.068 DBMET02227 | DBMET02227 | |
| 0.043 | 0.057 | 0.075 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.075 0.018 DBMET02227 | DBMET02227 | |
| 0.033 | 0.051 | 0.043 | Neurotensin receptor antagonist | 0.043 0.034 DBMET02227 | DBMET02227 | |
| 0.025 | 0.042 | 0.031 | Retinoid X alpha receptor agonist | 0.031 0.029 DBMET02229 | DBMET02229 | |
| 0.088 | 0.105 | 0.102 | Alkylator | 0.102 0.086 DBMET02227 | DBMET02227 | |
| 0.111 | 0.129 | 0.128 | Sigma receptor agonist | 0.124 0.11 DBMET02227 0.128 0.104 DBMET02229 | DBMET02229 | |
| 0.052 | 0.071 | 0.07 | Ryanodine receptor antagonist | 0.057 0.049 DBMET02227 0.07 0.017 DBMET02228 | DBMET02228 | |
| 0.034 | 0.056 | 0.055 | Ribonucleoside-diphosphate reductase inhibitor | 0.048 0.042 DBMET02227 0.055 0.037 DBMET02228 | DBMET02228 | |
| 0.031 | 0.053 | 0.211 | Aminopeptidase N inhibitor | 0.211 0.004 DBMET02228 | DBMET02228 | |
| 0.034 | 0.058 | 0.055 | Ribonucleotide reductase inhibitor | 0.048 0.043 DBMET02227 0.055 0.039 DBMET02228 | DBMET02228 | |
| 0.02 | 0.044 | 0.061 | Peptide deformylase inhibitor | 0.061 0.007 DBMET02228 | DBMET02228 | |
| 0.019 | 0.044 | 0.029 | Thyroid hormone agonist | 0.029 0.014 DBMET02227 | DBMET02227 | |
| 0.044 | 0.07 | 0.055 | TRPA1 antagonist | 0.055 0.051 DBMET02229 | DBMET02229 | |
| 0.016 | 0.042 | 0.022 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.022 0.02 DBMET02229 | DBMET02229 | |
| 0.045 | 0.074 | 0.125 | Matrix metalloproteinase inhibitor | 0.125 0.018 DBMET02228 | DBMET02228 | |
| 0.03 | 0.061 | 0.093 | Matrix metalloproteinase 1 inhibitor | 0.093 0.016 DBMET02228 | DBMET02228 | |
| 0.04 | 0.071 | 0.088 | Matrix metalloproteinase (membrane-type) inhibitor | 0.088 0.017 DBMET02228 | DBMET02228 | |
| 0.064 | 0.097 | 0.127 | Opioid antagonist | 0.127 0.033 DBMET02227 | DBMET02227 | |
| 0.058 | 0.091 | 0.144 | Metalloproteinase-2 inhibitor | 0.144 0.02 DBMET02228 | DBMET02228 | |
| 0.107 | 0.142 | 0.128 | Hexokinase inhibitor | 0.128 0.107 DBMET02227 | DBMET02227 | |
| 0.041 | 0.077 | 0.055 | Androgen agonist | 0.055 0.048 DBMET02227 0.055 0.048 DBMET02229 | DBMET02229 | |
| 0.042 | 0.08 | 0.08 | Botulinum neurotoxin type A inhibitor | 0.08 0.017 DBMET02228 | DBMET02228 | |
| 0.04 | 0.085 | 0.118 | Collagenase 3 inhibitor | 0.118 0.012 DBMET02228 | DBMET02228 | |
| 0.039 | 0.087 | 0.105 | Opioid mu receptor antagonist | 0.105 0.03 DBMET02227 | DBMET02227 | |
| 0.028 | 0.076 | 0.162 | Aggrecanase 1 inhibitor | 0.162 0.004 DBMET02228 | DBMET02228 | |
| 0.077 | 0.127 | 0.155 | Amylase inhibitor | 0.155 0.061 DBMET02227 | DBMET02227 | |
| 0.038 | 0.088 | 0.06 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.06 0.039 DBMET02227 | DBMET02227 | |
| 0.053 | 0.105 | 0.135 | Metalloproteinase-9 inhibitor | 0.135 0.02 DBMET02228 | DBMET02228 | |
| 0.021 | 0.073 | 0.108 | Histone deacetylase 7 inhibitor | 0.108 0.008 DBMET02228 | DBMET02228 | |
| 0.038 | 0.092 | 0.052 | Vanilloid 2 antagonist | 0.052 0.036 DBMET02227 | DBMET02227 | |
| 0.101 | 0.155 | 0.157 | Heat shock protein 90 antagonist | 0.157 0.068 DBMET02227 | DBMET02227 | |
| 0.045 | 0.106 | 0.077 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.077 0.054 DBMET02227 | DBMET02227 | |
| 0.017 | 0.079 | 0.039 | Carbonic anhydrase IV inhibitor | 0.039 0.035 DBMET02228 | DBMET02228 | |
| 0.025 | 0.089 | 0.066 | Metalloproteinase-3 inhibitor | 0.066 0.021 DBMET02228 | DBMET02228 | |
| 0.053 | 0.119 | 0.082 | NMDA receptor antagonist | 0.082 0.063 DBMET02227 | DBMET02227 | |
| 0.046 | 0.114 | 0.091 | Phosphodiesterase 1C inhibitor | 0.091 0.013 DBMET02228 | DBMET02228 | |
| 0.025 | 0.095 | 0.069 | Histone deacetylase 9 inhibitor | 0.069 0.01 DBMET02228 | DBMET02228 | |
| 0.055 | 0.131 | 0.084 | Estrogen receptor alpha antagonist | 0.084 0.042 DBMET02227 | DBMET02227 | |
| 0.032 | 0.109 | 0.065 | NMDA 2 receptor antagonist | 0.065 0.056 DBMET02227 | DBMET02227 | |
| 0.052 | 0.13 | 0.098 | Opioid kappa receptor antagonist | 0.098 0.037 DBMET02227 | DBMET02227 | |
| 0.139 | 0.217 | 0.263 | Lipoxygenase inhibitor | 0.231 0.113 DBMET02227 0.263 0.092 DBMET02228 0.186 0.156 DBMET02229 | DBMET02228 | |
| 0.102 | 0.19 | 0.268 | Tumour necrosis factor antagonist | 0.268 0.025 DBMET02228 | DBMET02228 | |
| 0.066 | 0.161 | 0.099 | Nav1.4 sodium channel blocker | 0.099 0.077 DBMET02227 | DBMET02227 | |
| 0.034 | 0.133 | 0.047 | Factor III inhibitor | 0.047 0.043 DBMET02227 | DBMET02227 | |
| 0.014 | 0.117 | 0.084 | Histone deacetylase 8 inhibitor | 0.084 0.01 DBMET02228 | DBMET02228 | |
| 0.055 | 0.158 | 0.091 | Phosphodiesterase I inhibitor | 0.091 0.057 DBMET02228 | DBMET02228 | |
| 0.133 | 0.238 | 0.28 | 12-Lipoxygenase inhibitor | 0.221 0.129 DBMET02227 0.208 0.142 DBMET02228 0.28 0.091 DBMET02229 | DBMET02229 | |
| 0.042 | 0.151 | 0.079 | Macrophage migration inhibitory factor inhibitor | 0.079 0.052 DBMET02227 | DBMET02227 | |
| 0.095 | 0.204 | 0.176 | DNA methylase inhibitor | 0.176 0.096 DBMET02228 | DBMET02228 | |
| 0.06 | 0.174 | 0.083 | Vanilloid agonist | 0.083 0.062 DBMET02227 | DBMET02227 | |
| 0.088 | 0.207 | 0.168 | DNA methyltransferase I inhibitor | 0.168 0.088 DBMET02228 | DBMET02228 | |
| 0.102 | 0.223 | 0.145 | Lipocortins synthesis antagonist | 0.145 0.113 DBMET02228 | DBMET02228 | |
| 0.032 | 0.157 | 0.072 | Phosphodiesterase 1B inhibitor | 0.072 0.028 DBMET02228 | DBMET02228 | |
| 0.035 | 0.167 | 0.074 | Analgesic, opioid | 0.074 0.056 DBMET02227 | DBMET02227 | |
| 0.014 | 0.146 | 0.043 | Opioid mu receptor agonist | 0.043 0.036 DBMET02227 | DBMET02227 | |
| 0.01 | 0.153 | 0.067 | Histone deacetylase class I inhibitor | 0.067 0.013 DBMET02228 | DBMET02228 | |
| 0.027 | 0.177 | 0.123 | Histone deacetylase inhibitor | 0.123 0.012 DBMET02228 | DBMET02228 | |
| 0.063 | 0.231 | 0.16 | Interleukin 4 antagonist | 0.16 0.042 DBMET02227 | DBMET02227 | |
| 0.052 | 0.224 | 0.08 | Thioredoxin reductase inhibitor | 0.08 0.061 DBMET02229 | DBMET02229 | |
| 0.101 | 0.274 | 0.155 | Death-associated protein kinase 2 inhibitor | 0.155 0.095 DBMET02228 | DBMET02228 | |
| 0.012 | 0.194 | 0.212 | Macrophage elastase inhibitor | 0.212 0.004 DBMET02228 | DBMET02228 | |
| 0.03 | 0.214 | 0.062 | DNA helicase inhibitor | 0.062 0.025 DBMET02229 | DBMET02229 | |
| 0.081 | 0.272 | 0.313 | Free radical scavenger | 0.313 0.048 DBMET02227 0.162 0.131 DBMET02229 | DBMET02227 | |
| 0.049 | 0.249 | 0.197 | Interleukin 1b antagonist | 0.197 0.02 DBMET02228 | DBMET02228 | |
| 0.045 | 0.25 | 0.103 | DNA polymerase I inhibitor | 0.103 0.083 DBMET02227 | DBMET02227 | |
| 0.02 | 0.227 | 0.119 | Nitric oxide donor | 0.119 0.004 DBMET02229 | DBMET02229 | |
| 0.053 | 0.269 | 0.162 | Angiogenesis stimulant | 0.162 0.115 DBMET02227 | DBMET02227 | |
| 0.045 | 0.262 | 0.106 | Bone formation stimulant | 0.106 0.099 DBMET02227 | DBMET02227 | |
| 0.067 | 0.299 | 0.144 | NOS3 expression enhancer | 0.144 0.078 DBMET02227 | DBMET02227 | |
| 0.01 | 0.251 | 0.157 | Collagenase inhibitor | 0.157 0.004 DBMET02228 | DBMET02228 | |
| 0.024 | 0.292 | 0.217 | 5-Lipoxygenase inhibitor | 0.088 0.073 DBMET02227 0.217 0.021 DBMET02228 | DBMET02228 | |
| 0.112 | 0.381 | 0.214 | Apoptosis antagonist | 0.214 0.163 DBMET02227 | DBMET02227 | |
| 0.103 | 0.379 | 0.291 | Sodium/bile acid cotransporter inhibitor | 0.291 0.088 DBMET02227 | DBMET02227 | |
| 0.004 | 0.309 | 0.053 | Aggrecanase 2 inhibitor | 0.053 0.005 DBMET02228 | DBMET02228 | |
| 0.06 | 0.377 | 0.366 | Antioxidant | 0.27 0.074 DBMET02227 0.366 0.042 DBMET02228 | DBMET02228 | |
| 0.005 | 0.326 | 0.308 | Histone deacetylase 10 inhibitor | 0.308 0.003 DBMET02228 | DBMET02228 | |
| 0.021 | 0.345 | 0.185 | M17 leucyl aminopeptidase inhibitor | 0.185 0.038 DBMET02228 | DBMET02228 | |
| 0.014 | 0.346 | 0.198 | ADAM10 endopeptidase inhibitor | 0.198 0.003 DBMET02228 | DBMET02228 | |
| 0.007 | 0.345 | 0.41 | Histone deacetylase 11 inhibitor | 0.41 0.003 DBMET02228 | DBMET02228 | |
| 0.007 | 0.345 | 0.41 | Histone deacetylase class IV inhibitor | 0.41 0.003 DBMET02228 | DBMET02228 | |
| 0.003 | 0.357 | 0.044 | Estrogen receptor alpha agonist | 0.044 0.019 DBMET02227 | DBMET02227 | |
| 0.066 | 0.433 | 0.169 | Hypoglycemic | 0.169 0.148 DBMET02227 | DBMET02227 | |
| 0.005 | 0.387 | 0.304 | Histone deacetylase 4 inhibitor | 0.304 0.003 DBMET02228 | DBMET02228 | |
| 0.017 | 0.43 | 0.107 | M18 aspartyl aminopeptidase inhibitor | 0.107 0.084 DBMET02227 | DBMET02227 | |
| 0.01 | 0.424 | 0.037 | Estrogen-related receptor beta antagonist | 0.037 0.014 DBMET02227 | DBMET02227 | |
| 0.034 | 0.459 | 0.113 | Interleukin 1 antagonist | 0.113 0.099 DBMET02228 | DBMET02228 | |
| 0.032 | 0.475 | 0.122 | Farnesoid X receptor antagonist | 0.122 0.1 DBMET02227 | DBMET02227 | |
| 0.003 | 0.456 | 0.037 | Estrogen receptor beta agonist | 0.037 0.022 DBMET02227 | DBMET02227 | |
| 0.021 | 0.477 | 0.137 | Lipid peroxidase inhibitor | 0.137 0.078 DBMET02227 | DBMET02227 | |
| 0.004 | 0.496 | 0.056 | Estrogen agonist | 0.056 0.032 DBMET02227 | DBMET02227 | |
| 0.004 | 0.503 | 0.467 | Histone deacetylase 3 inhibitor | 0.467 0.004 DBMET02228 | DBMET02228 | |
| 0.004 | 0.561 | 0.558 | Histone deacetylase 2 inhibitor | 0.558 0.004 DBMET02228 | DBMET02228 | |
| 0.017 | 0.577 | 0.212 | Viral attachment inhibitor | 0.212 0.005 DBMET02229 | DBMET02229 | |
| 0.004 | 0.583 | 0.674 | Histone deacetylase 1 inhibitor | 0.674 0.003 DBMET02228 | DBMET02228 | |
| 0.01 | 0.617 | 0.133 | Estrogen receptor beta antagonist | 0.133 0.021 DBMET02227 | DBMET02227 | |
| 0.004 | 0.615 | 0.451 | Histone deacetylase class IIa inhibitor | 0.451 0.003 DBMET02228 | DBMET02228 | |
| 0.004 | 0.63 | 0.077 | Aldose reductase inhibitor | 0.077 0.024 DBMET02229 | DBMET02229 | |
| 0.004 | 0.632 | 0.464 | Histone deacetylase 5 inhibitor | 0.464 0.003 DBMET02228 | DBMET02228 | |
| 0.012 | 0.68 | 0.142 | Estrogen antagonist | 0.142 0.027 DBMET02227 | DBMET02227 | |
| 0.004 | 0.698 | 0.079 | Phosphodiesterase 4C inhibitor | 0.079 0.021 DBMET02228 | DBMET02228 | |
| 0.004 | 0.742 | 0.666 | Histone deacetylase class IIb inhibitor | 0.666 0.003 DBMET02228 | DBMET02228 | |
| 0.004 | 0.743 | 0.667 | Histone deacetylase 6 inhibitor | 0.667 0.003 DBMET02228 | DBMET02228 | |
| 0.004 | 0.764 | 0.676 | Histone deacetylase class II inhibitor | 0.676 0.003 DBMET02228 | DBMET02228 | |
| 0.011 | 0.778 | 0.568 | Tumour necrosis factor alpha release inhibitor | 0.568 0.009 DBMET02228 | DBMET02228 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |